Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.
OBJECTIVE
We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count.


METHODS
Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs).


RESULTS
We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively).


CONCLUSIONS
We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease.
Sciarra
Alessandro
A
Department of Urology, University of La Sapienza, Rome, Italy. sciarrajr@hotmail.com
Lichtner
Miriam
M
Autran
Gomez AnnaMaria
GA
Mastroianni
Claudio
C
Rossi
Raffaella
R
Mengoni
Fabio
F
Cristini
Cristiano
C
Gentilucci
Alessandro
A
Vullo
Vincenzo
V
Di Silverio
Franco
F
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D002452:Cell Count; D003713:Dendritic Cells / Q000145:classification / Q000378:metabolism / Q000473:pathology*; D018450:Disease Progression; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D022423:Myeloid Cells / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*